{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T14:23:58Z","timestamp":1788186238043,"version":"build-2803163510"},"reference-count":23,"publisher":"Pharmaceutical Society of Japan","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2022,10,1]]},"DOI":"10.1248\/bpb.b22-00404","type":"journal-article","created":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T22:24:38Z","timestamp":1664576678000},"page":"1531-1536","source":"Crossref","is-referenced-by-count":5,"title":["Prevention of Acne-Like Eruption Caused by Panitumumab Treatment through Oral Administration of Non-steroidal Anti-inflammatory Drugs"],"prefix":"10.1248","volume":"45","author":[{"given":"Rei","family":"Tanaka","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Shizuoka Cancer Center"},{"name":"Faculty of Pharmaceutical Sciences, Tokyo University of Science"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Ishikawa","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shizuoka Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junya","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shizuoka Cancer Center"},{"name":"Department of Pharmacy, International University of Health and Welfare Hospital"},{"name":"School of Pharmacy, International University of Health and Welfare"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takao","family":"Aoyama","sequence":"additional","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, Tokyo University of Science"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Shikamura","sequence":"additional","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, Tokyo University of Science"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiro","family":"Shino","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shizuoka Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) K\u00f6hne CH, Hofheinz R, Mineur L, Letocha H, Greil R, Thaler J, Fernebro E, Gamelin E, Decosta L, Karthaus M. First-line panitumumab plus irinotecan\/5-fluorouracil\/leucovorin treatment in patients with metastatic colorectal cancer. <i>J. Cancer Res. Clin. Oncol.<\/i>, <b>138<\/b>, 65\u201372 (2012).","DOI":"10.1007\/s00432-011-1061-6"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Koc\u00e1kova I, Ruff P, B\u0142asi\u0144ska-Morawiec M, \u0160makal M, Canon JL, Rother M, Oliner KS, Wolf M, Gansert J. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) <i>versus<\/i> FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. <i>J. Clin. Oncol.<\/i>, <b>28<\/b>, 4697\u20134705 (2010).","DOI":"10.1200\/JCO.2009.27.4860"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Van Cutsem E, K\u00f6hne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D\u2019Haens G, Pint\u00e9r T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. <i>N. Engl. J. Med.<\/i>, <b>360<\/b>, 1408\u20131417 (2009).","DOI":"10.1056\/NEJMoa0805019"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Ninomiya K, Teraoka S, Zenke Y, <i>et al.<\/i> Japanese lung cancer society guidelines for Stage IV NSCLC with EGFR mutations. <i>JTO Clin. Res. Rep.<\/i>, <b>2<\/b>, 100107 (2021).","DOI":"10.1016\/j.jtocrr.2020.100107"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Price T, Kim TW, Li J, Cascinu S, Ruff P, Suresh AS, Thomas A, Tjulandin S, Guan X, Peeters M. Final results and outcomes by prior bevacizumab exposure, skin toxicity, and hypomagnesaemia from ASPECCT: randomized phase 3 non-inferiority study of panitumumab <i>versus<\/i> cetuximab in chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer. <i>Eur. J. Cancer<\/i>, <b>68<\/b>, 51\u201359 (2016).","DOI":"10.1016\/j.ejca.2016.08.010"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Lacouture ME, Mitchell EP, Piperdi B, Pillai MV, Shearer H, Iannotti N, Xu F, Yassine M. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. <i>J. Clin. Oncol.<\/i>, <b>28<\/b>, 1351\u20131357 (2010).","DOI":"10.1200\/JCO.2008.21.7828"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Kobayashi Y, Komatsu Y, Yuki S, <i>et al.<\/i> Randomized controlled trial on the skin toxicity of panitumumab in Japanese patients with metastatic colorectal cancer: HGCSG1001 study; J-STEPP. <i>Future Oncol.<\/i>, <b>11<\/b>, 617\u2013627 (2015).","DOI":"10.2217\/fon.14.251"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Iimura Y, Shimomura H, Yasu T, Imanaka K, Ogawa R, Ito A, Suzuki K, Yamaguchi G, Kawasaki N, Konaka C. NSAIDs may prevent EGFR-TKI-related skin rash in non-small cell lung cancer patients. <i>Int. J. Clin. Pharmacol. Ther.<\/i>, <b>56<\/b>, 551\u2013554 (2018).","DOI":"10.5414\/CP203323"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Kanazawa S, Yamaguchi K, Kinoshita Y, Muramatsu M, Komiyama Y, Nomura S. Aspirin reduces adverse effects of gefitinib. <i>Anticancer Drugs<\/i>, <b>17<\/b>, 423\u2013427 (2006).","DOI":"10.1097\/01.cad.0000203385.45163.76"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Ashida A, Ogawa E, Uhara H, Koizumi T, Okuyama R. Inhibition of epidermal growth factor receptor induces tumor necrosis factor-\u03b1 <i>via<\/i> activation of peroxisome proliferator-activated receptor-\u03b3 and nuclear factor-\u03baB in sebocytes: a possible pathogenesis of papulopustular rash. <i>J. Dermatol. Sci.<\/i>, <b>82<\/b>, 53\u201356 (2016).","DOI":"10.1016\/j.jdermsci.2015.12.004"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Jatoi A, Green EM, Rowland KM Jr, Sargent DJ, Alberts SR. Clinical predictors of severe cetuximab-induced rash: observations from 933 patients enrolled in north central cancer treatment group study N0147. <i>Oncology<\/i>, <b>77<\/b>, 120\u2013123 (2009).","DOI":"10.1159\/000229751"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Miyawaki S, Tohyama M, Irifune K, Ito R, Sayama K. Pressure sore-like ulcers on acneiform papules caused by EGFR inhibitors. <i>Int. Wound J.<\/i>, <b>11<\/b>, 569\u2013570 (2014).","DOI":"10.1111\/iwj.12070"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Henehan M, Montuno M, De Benedetto A. Doxycycline as an anti-inflammatory agent: updates in dermatology. <i>J. Eur. Acad. Dermatol. Venereol.<\/i>, <b>31<\/b>, 1800\u20131808 (2017).","DOI":"10.1111\/jdv.14345"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Gu Y, Lee HM, Sorsa T, Salminen A, Ryan ME, Slepian MJ, Golub LM. Non-antibacterial tetracyclines modulate mediators of periodontitis and atherosclerotic cardiovascular disease: A mechanistic link between local and systemic inflammation. <i>Pharmacol. Res.<\/i>, <b>64<\/b>, 573\u2013579 (2011).","DOI":"10.1016\/j.phrs.2011.06.023"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Stechmiller J, Cowan L, Schultz G. The role of doxycycline as a matrix metalloproteinase inhibitor for the treatment of chronic wounds. <i>Biol. Res. Nurs.<\/i>, <b>11<\/b>, 336\u2013344 (2010).","DOI":"10.1177\/1099800409346333"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Wong RC, Kang S, Heezen JL, Voorhees JJ, Ellis CN. Oral ibuprofen and tetracycline for the treatment of acne vulgaris. <i>J. Am. Acad. Dermatol.<\/i>, <b>11<\/b>, 1076\u20131081 (1984).","DOI":"10.1016\/S0190-9622(84)80192-9"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Lanas A, Garc\u00eda-Rodr\u00edguez LA, Arroyo MT, Gomoll\u00f3n F, Feu F, Gonz\u00e1lez-P\u00e9rez A, Zapata E, B\u00e1stida G, Rodrigo L, Santolaria S, G\u00fcell M, de Argila CM, Quintero E, Borda F, Piqu\u00e9 JM. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. <i>Gut<\/i>, <b>55<\/b>, 1731\u20131738 (2006).","DOI":"10.1136\/gut.2005.080754"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Hern\u00e1ndez-D\u00edaz S, Rodr\u00edguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding\/perforation: an overview of epidemiologic studies published in the 1990s. <i>Arch. Intern. Med.<\/i>, <b>160<\/b>, 2093\u20132099 (2000).","DOI":"10.1001\/archinte.160.14.2093"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Arai T, Fujita Y, Imai H, Matsumoto H, Yamazaki M, Hiruta E, Suzuki Y, Ojima H, Hosaka H, Minato K, Saito T. Effects of sex and seasonal climatic changes on the risk of incidence of anti-EGFR therapy-induced rash in cancer patients: a retrospective study. <i>Medicina<\/i> (Kaunas), <b>57<\/b>, 801 (2021).","DOI":"10.3390\/medicina57080801"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Holman DM, Berkowitz Z, Guy GP Jr, Hawkins NA, Saraiya M, Watson M. Patterns of sunscreen use on the face and other exposed skin among U.S. adults. <i>J. Am. Acad. Dermatol.<\/i>, <b>73<\/b>, 83\u201392.e1 (2015).","DOI":"10.1016\/j.jaad.2015.02.1112"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Gooch K, Culleton BF, Manns BJ, Zhang J, Alfonso H, Tonelli M, Frank C, Klarenbach S, Hemmelgarn BR. NSAID use and progression of chronic kidney disease. <i>Am. J. Med.<\/i>, <b>120<\/b>, 280.e1\u2013e7 (2007).","DOI":"10.1016\/j.amjmed.2006.02.015"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Sato J, Ishikawa H, Hamauchi S, Yamawaki Y, Mori K, Kiyohara Y, Yoshikawa S, Yamazaki K, Yasui H, Shino M. Adherence to a topical moisturizing preparation for regorafenib-related hand-foot skin reaction. <i>J. Oncol. Pharm. Pract.<\/i>, <b>26<\/b>, 361\u2013367 (2020).","DOI":"10.1177\/1078155219849275"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Levine JM. Clinical aspects of aging skin: considerations for the wound care practitioner. <i>Adv. Skin Wound Care<\/i>, <b>33<\/b>, 12\u201319 (2020).","DOI":"10.1097\/01.ASW.0000613532.25408.8b"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/45\/10\/45_b22-00404\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T05:31:11Z","timestamp":1715232671000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/45\/10\/45_b22-00404\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,1]]},"references-count":23,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b22-00404","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,1]]},"article-number":"b22-00404"}}